SCHEDULE 13G 0001463928 XXXXXXXX LIVE American Depository Shares, each representing 4,000 Ordinary Shares, no par value 03/24/2025 0001611747 Scinai Immunotherapeutics Ltd. 09073Q203 Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem L3 000000 Rule 13d-1(c) YA II PN, Ltd. a E9 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. YA Global Investments II (U.S.), LP a DE 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. Yorkville Advisors Global, LP a DE 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. Yorkville Advisors Global II, LLC a DE 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. YAII GP, LP a DE 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. YAII GP II, LLC a DE 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. Mark Angelo a NJ 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. SC-Sigma Global Partners, LP a DE 0.00 93274.00 0.00 93274.00 93274.00 N 9.9 OO Based on 933,679 ADSs outstanding as reported by Scinai Immunotherapeutics Ltd. (the "Issuer") on March 11, 2025. YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with the Issuer on March 3, 2025. Under the SEPA, the Issuer has the option to sell up to $10 million of its American Depositary Shares ("ADSs") to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of ADSs beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding ADSs of the Issuer. Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel, 000000 YA II PN, Ltd. 1012 Springfield Ave., Mountainside, NJ 07092 Cayman Islands N OO 93,274 9.9 0 93,274 0 93,274 Y Y Y N YA II is beneficially owned by YA Global Investments II (U.S.), LP (the "YA Feeder"). Yorkville Advisors Global, LP (the "YA Advisor") is the investment manager to YA II. Yorkville Advisors Global II, LLC (the "YA Advisor GP") is the general partner to the YA Advisor. YAII GP, LP (the "YA GP") is the general partner to the YA Feeder. YAII GP II, LLC (the "Yorkville GP") is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of ADSs. YAII GP, LP is the general partner of SC-Sigma Global Partners, LP ("SC-Sigma"), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of ADSs. For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person. Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. YA II PN, Ltd. /s/ David Gonzalez 03/26/2025 YA Global Investments II (U.S.), LP /s/ David Gonzalez 03/26/2025 Yorkville Advisors Global, LP /s/ David Gonzalez 03/26/2025 Yorkville Advisors Global II, LLC /s/ David Gonzalez 03/26/2025 YAII GP, LP /s/ David Gonzalez 03/26/2025 YAII GP II, LLC /s/ David Gonzalez 03/26/2025 Mark Angelo /s/ Mark Angelo 03/26/2025 SC-Sigma Global Partners, LP /s/ David Gonzalez 03/26/2025